Historical record - last NADAC effective date: 11/22/2023
Product Information
CLOBETASOL 0.05% OINTMENT is a generic product labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., priced at $0.1772 per GM under NDC 00168016260. Its NADAC has been published 523 times since Nov 28, 2013.
FDA first approved this application on Feb 23, 1996. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/g
NDC
00168016260
Classification
Generic
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
11/22/2023
Active Ingredients
CLOBETASOL PROPIONATEApproval Type
Generic (ANDA)
FDA Application
ANDA074407FDA Approved
2/23/1996
TE Code
AB
On Market Since
2/23/1996
Pharmacological Classes
Price Statistics
The NADAC for CLOBETASOL 0.05% OINTMENT has been published 523 times since Nov 28, 2013, and over the history we have for it it has declined 28.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1772 per GM |
|---|---|
| All-time high | $5.0089 (Jan 14, 2015) |
| All-time low | $0.1468 (Sep 20, 2023) |
| Median price | $0.5396 |
| Average price | $1.4352 |
| Largest weekly change | +1712.1% (Sep 10, 2014) |
| Weeks tracked | 523 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+20.7%
5Y
-58.7%
All
-28.6%
Last surveyed Nov 29, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 39% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
clobetasol propionate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLOBETASOL 0.05% OINTMENT?
The current National Average Drug Acquisition Cost (NADAC) for CLOBETASOL 0.05% OINTMENT, manufactured by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., is $0.1772 per GM (NDC 00168016260), effective Nov 29, 2023.
How has the price of CLOBETASOL 0.05% OINTMENT changed over time?
Over the history we have for it, the NADAC for CLOBETASOL 0.05% OINTMENT has declined 28.6%. It has been tracked across 523 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CLOBETASOL 0.05% OINTMENT?
Since Nov 28, 2013, the NADAC for CLOBETASOL 0.05% OINTMENT has ranged from a low of $0.1468 (Sep 20, 2023) to a high of $5.0089 (Jan 14, 2015), with a median of $0.5396 per GM.
Are there cheaper alternatives to CLOBETASOL 0.05% OINTMENT?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLOBETASOL 0.05% OINTMENT, is $0.1083 per GM — about 39% below CLOBETASOL 0.05% OINTMENT.
Who manufactures CLOBETASOL 0.05% OINTMENT?
CLOBETASOL 0.05% OINTMENT (NDC 00168016260) is labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., and CMS classifies it as a generic product.